Optimization of prediction methods for risk assessment of pathogenic germline variants in the Japanese population.


Journal

Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776

Informations de publication

Date de publication:
Aug 2021
Historique:
revised: 30 04 2021
received: 16 10 2020
accepted: 06 05 2021
pubmed: 27 5 2021
medline: 20 8 2021
entrez: 26 5 2021
Statut: ppublish

Résumé

Predicting pathogenic germline variants (PGVs) in breast cancer patients is important for selecting optimal therapeutics and implementing risk reduction strategies. However, PGV risk factors and the performance of prediction methods in the Japanese population remain unclear. We investigated clinicopathological risk factors using the Tyrer-Cuzick (TC) breast cancer risk evaluation tool to predict BRCA PGVs in unselected Japanese breast cancer patients (n = 1,995). Eleven breast cancer susceptibility genes were analyzed using target-capture sequencing in a previous study; the PGV prevalence in BRCA1, BRCA2, and PALB2 was 0.75%, 3.1%, and 0.45%, respectively. Significant associations were found between the presence of BRCA PGVs and early disease onset, number of familial cancer cases (up to third-degree relatives), triple-negative breast cancer patients under the age of 60, and ovarian cancer history (all P < .0001). In total, 816 patients (40.9%) satisfied the National Comprehensive Cancer Network (NCCN) guidelines for recommending multigene testing. The sensitivity and specificity of the NCCN criteria for discriminating PGV carriers from noncarriers were 71.3% and 60.7%, respectively. The TC model showed good discrimination for predicting BRCA PGVs (area under the curve, 0.75; 95% confidence interval, 0.69-0.81). Furthermore, use of the TC model with an optimized cutoff of TC score ≥0.16% in addition to the NCCN guidelines improved the predictive efficiency for high-risk groups (sensitivity, 77.2%; specificity, 54.8%; about 11 genes). Given the influence of ethnic differences on prediction, we consider that further studies are warranted to elucidate the role of environmental and genetic factors for realizing precise prediction.

Identifiants

pubmed: 34036661
doi: 10.1111/cas.14986
pmc: PMC8353892
doi:

Substances chimiques

BRCA1 Protein 0
BRCA1 protein, human 0
BRCA2 Protein 0
BRCA2 protein, human 0
Fanconi Anemia Complementation Group N Protein 0
PALB2 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3338-3348

Subventions

Organisme : AstraZeneca
ID : NCR-17-12919

Informations de copyright

© 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Références

Breast Cancer Res. 2011;13(6):223
pubmed: 22114898
Breast Cancer. 2020 May;27(3):322-331
pubmed: 32240526
JAMA. 2019 Aug 20;322(7):652-665
pubmed: 31429903
JAMA. 2015 Apr 7;313(13):1347-61
pubmed: 25849179
N Engl J Med. 2000 Jul 13;343(2):78-85
pubmed: 10891514
Clin Epidemiol. 2019 Jul 11;11:543-561
pubmed: 31372057
Dtsch Arztebl Int. 2011 May;108(19):323-30
pubmed: 21637635
N Engl J Med. 1997 Sep 11;337(11):788-9
pubmed: 9289641
N Engl J Med. 2008 Nov 13;359(20):2143-53
pubmed: 19005198
Int J Cancer. 2019 Aug 15;145(4):962-973
pubmed: 30702160
Breast Cancer. 2015 Sep;22(5):462-8
pubmed: 24249303
Commun Biol. 2020 Oct 16;3(1):578
pubmed: 33067557
Clin Cancer Res. 2017 Oct 15;23(20):6113-6119
pubmed: 28724667
Cancer. 2015 Jan 1;121(1):25-33
pubmed: 25186627
Biomed Res Int. 2013;2013:747318
pubmed: 23586058
Genet Med. 2019 Aug;21(8):1708-1718
pubmed: 30643217
Clin Cancer Res. 2016 Aug 1;22(15):3971-81
pubmed: 26979395
Jpn J Clin Oncol. 2015 Sep;45(9):884-91
pubmed: 26142437
Cancer Sci. 2021 Aug;112(8):3338-3348
pubmed: 34036661
Cell. 2013 Jan 31;152(3):633-41
pubmed: 23374354
Cancer Inform. 2015 May 10;14(Suppl 2):147-57
pubmed: 25983549
J Clin Oncol. 2014 May 20;32(15):1547-53
pubmed: 24567435
Stat Med. 2004 Apr 15;23(7):1111-30
pubmed: 15057881
N Engl J Med. 2021 Feb 4;384(5):428-439
pubmed: 33471991
Lancet. 2008 Feb 16;371(9612):569-78
pubmed: 18280327
Nat Commun. 2018 Oct 4;9(1):4083
pubmed: 30287823
J Clin Oncol. 2020 May 1;38(13):1409-1418
pubmed: 32125938
J Clin Oncol. 2016 May 1;34(13):1460-8
pubmed: 26976419
J Natl Compr Canc Netw. 2020 Apr;18(4):380-391
pubmed: 32259785
N Engl J Med. 2015 Jun 4;372(23):2243-57
pubmed: 26014596
Int J Cancer. 2017 Jul 1;141(1):129-142
pubmed: 28294317
N Engl J Med. 2021 Feb 4;384(5):440-451
pubmed: 33471974
Fam Cancer. 2010 Dec;9(4):495-502
pubmed: 20512419
Am J Surg. 2020 Jan;219(1):145-149
pubmed: 31255259
Ann Surg Oncol. 2010 Oct;17 Suppl 3:211-8
pubmed: 20853035
Science. 1994 Oct 7;266(5182):66-71
pubmed: 7545954
NPJ Breast Cancer. 2020 Jun 12;6:25
pubmed: 32566746
JAMA Surg. 2017 Jun 1;152(6):589-594
pubmed: 28423155
PLoS Med. 2017 Jun 30;14(6):e1002335
pubmed: 28666001
J Clin Oncol. 2020 Jun 20;38(18):2080-2106
pubmed: 32243226

Auteurs

Noriko Senda (N)

Department of Breast Surgery, Kyoto University, Kyoto, Japan.

Nobuko Kawaguchi-Sakita (N)

Department of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan.

Masahiro Kawashima (M)

Department of Breast Surgery, Kyoto University, Kyoto, Japan.

Yukiko Inagaki-Kawata (Y)

Department of Breast Surgery, Kyoto University, Kyoto, Japan.

Kenichi Yoshida (K)

Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.

Masahiro Takada (M)

Department of Breast Surgery, Kyoto University, Kyoto, Japan.

Masako Kataoka (M)

Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University, Kyoto, Japan.

Masae Torii (M)

Department of Breast Surgery, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan.

Tomomi Nishimura (T)

Department of Breast Surgery, Kyoto University, Kyoto, Japan.

Kosuke Kawaguchi (K)

Department of Breast Surgery, Kyoto University, Kyoto, Japan.

Eiji Suzuki (E)

Department of Breast Surgery, Kyoto University, Kyoto, Japan.

Yuki Kataoka (Y)

Department of Healthcare Epidemiology, School of Public Health, in the Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Yoshiaki Matsumoto (Y)

Department of Breast Surgery, Kyoto University, Kyoto, Japan.

Hiroshi Yoshibayashi (H)

Department of Breast Surgery, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan.

Kazuhiko Yamagami (K)

Department of Breast Surgery and Oncology, Shinko Hospital, Kobe, Japan.

Shigeru Tsuyuki (S)

Department of Breast Surgery, Osaka Red Cross Hospital, Osaka, Japan.

Sachiko Takahara (S)

Department of Breast Surgery, Kitano Hospital, Osaka, Japan.

Akira Yamauchi (A)

Department of Breast Surgery, Kitano Hospital, Osaka, Japan.

Nobuhiko Shinkura (N)

Department of Surgery, Ijinkai Takeda General Hospital, Kyoto, Japan.

Hironori Kato (H)

Department of Breast Surgery, Kobe City Medical Center General Hospital, Kobe, Japan.

Yoshio Moriguchi (Y)

Department of Breast Surgery, Kyoto City Hospital, Kyoto, Japan.

Ryuji Okamura (R)

Department of Breast Surgery, Yamatotakada Municipal Hospital, Yamatotakada, Japan.

Norimichi Kan (N)

Kan Norimichi Clinic, Kyoto, Japan.

Hirofumi Suwa (H)

Department of Breast Surgery, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan.

Shingo Sakata (S)

Department of Breast Surgery, Rakuwakai Otowa Hospital, Kyoto, Japan.

Susumu Mashima (S)

Department of Surgery, Japan Community Health Care Organization, Yamato Koriyama Hospital, Yamato Koriyama, Japan.

Fumiaki Yotsumoto (F)

Department of Breast Surgery, Shiga General Hospital, Moriyama, Japan.

Tsuyoshi Tachibana (T)

Department of Breast Surgery, Otsu City Hospital, Otsu, Japan.

Mitsuru Tanaka (M)

Department of Surgery, Hirakata Kohsai Hospital, Hirakata, Japan.

Kaori Togashi (K)

Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University, Kyoto, Japan.

Hironori Haga (H)

Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.

Takahiro Yamada (T)

Department of Medical Ethics/Medical Genetics, Kyoto University, Kyoto, Japan.

Shinji Kosugi (S)

Department of Medical Ethics/Medical Genetics, Kyoto University, Kyoto, Japan.

Takashi Inamoto (T)

Faculty of Health Care, Tenri Health Care University, Tenri, Japan.

Masahiro Sugimoto (M)

Health Promotion and Preemptive Medicine, Research and Development Center for Minimally Invasive Therapies, Tokyo Medical University, Tokyo, Japan.

Seishi Ogawa (S)

Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.

Masakazu Toi (M)

Department of Breast Surgery, Kyoto University, Kyoto, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH